As researchers from more than 110 countries gathered for the Alzheimer’s Association International Conference, new data estimate the number of people with dementia globally will triple to more than 152 million by 2050.

In this episode, BioWorld Staff Writer Lee Landenberger spoke with Howard Fillit, founding executive director and chief science officer at the Alzheimer’s Drug Discovery Foundation, which was created to accelerate the discovery of drugs to prevent, treat and cure Alzheimer's disease. The geriatrician, neuroscientist and Mount Sinai School of Medicine professor has led the foundation since it was formed in 1998. He’s seen a lot of change in the R&D of dementia treatments and shared his insights about the importance of biomarkers, the controversy surrounding Biogen Inc.'s recently approved Aduhelm (aducanumab) and the impact of financial investments that drive the development of these therapies compared to other indications.

Download transcript

Biopharma deal-making activity, a closely-watched marker of industry health, remained alive and well in Q2. But whither M&A? And what’s with all those $1 billion-plus deals? Join News Editor Michael Fitzhugh and BioWorld Senior Analyst Karen Carey as they chat about the latest currents in combinations, partnerships amid the pandemic, and the rising values of up-front payments – at least for those clinical-stage companies lucky enough to make lucrative deals ahead of commercialization.

BioWorld subscribers looking for an even deeper dive on the numbers can read Karen’s Q2 Deals and M&A overview, including overviews M&A value and volume by year, a list of the year’s top M&A deals to date – led by Jazz Pharmaceuticals plc’s takeout of GW Pharmaceuticals plc – and even more details about the world of biopharma deals in BioWorld Snapshots.

Download transcript

Iteos Therapeutics Inc. has come a long way in the past year. The company went public in July 2020 and this week inked a deal with Glaxosmithkline plc (GSK) that could top $2 billion. Iteos brings GSK a human monoclonal antibody targeting TIGIT, the third of the known CD226 checkpoints that the company wanted for its cancer therapy program. The two companies plan to split U.S. profits, something that Iteos insisted upon as part of the deal. Iteos is receiving $625 million as an up-front payment and up to $1.45 billion in potential milestone payments.

In this episode, BioWorld Staff Writer Lee Landenberger caught up with Michel Detheux, president and CEO of Iteos, who said the company was in a strong financial position and didn’t need a deal this size, but the cash infusion will significantly boost its PD-1 development programs.

Download transcript

The FDA’s accelerated approval of Biogen Inc.’s Alzheimer’s disease therapy, Aduhelm (aducanumab), is the first real beacon of hope in 18 years for the 50 million people living with the disease. But the approval was met with controversy over the drug’s efficacy and pricing. Even as Biogen readies to launch in just two weeks with more than 900 sites lined up to start treating patients, a required confirmatory study could sink everything.

BioWorld has been reporting on the development of Aduhelm since its discovery, by way of Neurimmune AG’s reverse translational medicine technology. Later licensed to Biogen, it was co-developed with Eisai Co. Ltd.

In this episode, News Editor Michael Fitzhugh talks with Ivana Rubino, Biogen’s VP of global and U.S. medical affairs for Alzheimer’s disease, about the approval, the controversies and what it all means for Biogen’s future.

Download transcipt